(3S)-3-(1-methylindol-3-yl)-N-(2-piperidin-1-ylethyl)-3-[3-(trifluoromethyl)phenyl]propanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3S)-3-(1-methylindol-3-yl)-N-(2-piperidin-1-ylethyl)-3-[3-(trifluoromethyl)phenyl]propanamide
• 化学式: C₂₆H₃₀F₃N₃O
• 分子量: 457.5
• InChiKey: GHWTVDWUJLEODG-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• MITOKETOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING KETONE METABOLISM IN CANCER CELLS
  申请人：LUNELLA BIOTECH, INC.

  公开号：US20200148688A1

  公开（公告）日：2020-05-14

  The present disclosure relates to compounds that bind to at least one of ACAT1/2 and OXCT1/2 and inhibit mitochondrial ATP production, referred to herein as mitoketoscins. Methods of screening compounds for mitochondrial inhibition and anti-cancer properties are disclosed. Also described are methods of using mitoketoscins to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitoketoscins to provide anti-aging benefits. Specific mitoketoscin compounds are also disclosed.
• BIOMARKERS AND THERAPEUTICS FOR ENDOCRINE THERAPY RESISTANCE
  申请人：LUNELLA BIOTECH, INC.

  公开号：US20210215702A1

  公开（公告）日：2021-07-15

  Cancer cells can develop resistance to endocrine therapies, such as Tamoxifen, through acquisition of the Y537S mutation. Cells transfected with the Y537S mutation showed significant increases in mitochondrial mass and membrane potential, consistent with an increase in mitochondrial biogenesis. Certain biomarkers are identified that have prognostic value of endocrine therapy resistance. The mechanism resulting in this resistance, however, leaves these treatment-resistant cells vulnerable to therapeutics that inhibit mitochondrial biogenesis. Numerous mitochondrial biogenesis inhibitors are disclosed, as well as methods for reducing or eliminating endocrine treatment resistance, improving the effectiveness of an endocrine therapy, and for treating cancer.